Williams Jeannette N, Skipp Paul J, Humphries Holly E, Christodoulides Myron, O'Connor C David, Heckels John E
Molecular Microbiology Group, Division of Infection Inflammation and Repair, University of Southampton Medical School, Southampton General Hospital, Southampton SO16 6YD, United Kingdom.
Infect Immun. 2007 Mar;75(3):1364-72. doi: 10.1128/IAI.01424-06. Epub 2006 Dec 11.
Current experimental vaccines against serogroup B Neisseria meningitidis are based on meningococcal outer membrane (OM) proteins present in outer membrane vesicles (OMV) in which toxic lipopolysaccharide is depleted by detergent extraction. Knowledge of the composition of OM and OMV is essential for developing new meningococcal vaccines based on defined antigens. In the current study, sodium dodecyl sulfate-polyacrylamide gel electrophoresis and nanocapillary liquid chromatography-tandem mass spectrometry were used to investigate the proteomes of OM and OMV from meningococcal strain MC58 and OM from a lipopolysaccharide-deficient mutant. The analysis of OM revealed a composition that was much more complex than the composition that has been reported previously; a total of 236 proteins were identified, only 6.4% of which were predicted to be located in the outer membrane. The most abundant proteins included not only the well-established major OM proteins (PorA, PorB, Opc, Rmp, and Opa) but also other proteins, such as pilus-associated protein Q (PilQ) and a putative macrophage infectivity protein. All of these proteins were also present in OMV obtained by extraction of the OM with deoxycholate. There were markedly increased levels of some additional proteins in OM from the lipopolysaccharide-deficient mutant, including enzymes that contribute to the tricarboxylic acid cycle. In all the preparations, the proteins not predicted to have an OM location were predominantly periplasmic or cytoplasmic or had an unknown location, and relatively few cytoplasmic membrane proteins were detected. However, several proteins that have previously been identified as potential vaccine candidates were not detected in either OM preparations or in OMV. These results have important implications for the development and use of vaccines based on outer membrane proteins.
目前针对B群脑膜炎奈瑟菌的实验性疫苗是基于存在于外膜囊泡(OMV)中的脑膜炎球菌外膜(OM)蛋白,其中有毒的脂多糖通过去污剂提取被去除。了解OM和OMV的组成对于开发基于特定抗原的新型脑膜炎球菌疫苗至关重要。在本研究中,使用十二烷基硫酸钠-聚丙烯酰胺凝胶电泳和纳升毛细管液相色谱-串联质谱来研究脑膜炎球菌菌株MC58的OM和OMV以及脂多糖缺陷型突变体的OM的蛋白质组。对OM的分析揭示了一种比先前报道的组成更为复杂的组成;总共鉴定出236种蛋白质,其中只有6.4%预计位于外膜。最丰富的蛋白质不仅包括公认的主要OM蛋白(PorA、PorB、Opc、Rmp和Opa),还包括其他蛋白质,如菌毛相关蛋白Q(PilQ)和一种假定的巨噬细胞感染性蛋白。所有这些蛋白质也存在于通过用脱氧胆酸盐提取OM而获得的OMV中。脂多糖缺陷型突变体的OM中一些其他蛋白质的水平明显增加,包括参与三羧酸循环的酶。在所有制剂中,预计不在OM位置的蛋白质主要是周质或细胞质的,或者位置未知,并且检测到的细胞质膜蛋白相对较少。然而,先前被鉴定为潜在疫苗候选物的几种蛋白质在OM制剂或OMV中均未检测到。这些结果对基于外膜蛋白的疫苗的开发和使用具有重要意义。